The Global Acute Intermittent Porphyria industry is projected to grow from USD 4.61 Billion in 2024 to USD 7.34 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.90% during the forecast period (2024 - 2032).
The risk factors associated with acute
intermittent porphyria, which include liver cancer (hepatocellular carcinoma),
kidney failure, neurological disorders, psychiatric issues, gastrointestinal
problems, urinary tract issues, etc. will accelerate the market expansion. The
growth of the market is also attributable to the increasing prevalence of the metabolic disorders which is likely to
increase further during the assessment
period.
Other factors responsible for the market proliferation include developments in the healthcare sector, adoption of latest technologies for diagnosis, drug discoveries for treatment, clinical trials by key players, increased disposable income, population explosion, etc. However, factors that will restrict the market growth across the assessment period include the availability of expensive treatment and poor reimbursement policies in the developing regions.
Market
Segmentation:
By diagnosis, the global acute
intermittent porphyria market has been
segmented into blood test, urine test, serum test, DNA test, and
others.
By treatment, acute intermittent porphyria
market is segmented into
gonadotropin-releasing hormone analogues,
prophylactic hematin infusions, and others.
By end user, the global acute intermittent
porphyria market has been segmented into
hospitals & clinics, research centers, and others.
Regional
Analysis:
By region, the acute intermittent porphyria
market has been segmented into North
America & South America, Europe, Asia Pacific, and, the Middle East &
Africa. The North America & South America region will generate maximum
revenue from the market during the projection period. The technological
advancements integrated into the treatment of acute intermittent porphyria is
likely to accelerate revenue creation over the review period. Other factors
responsible for the growth of the market include increasing patient with
genetic metabolic disorders, rising healthcare
expenditure, and increasing government
support for research & development. Furthermore, the concentration of key players in the region coupled with
increased research & development activities will encourage the market
growth and expansion.
Europe is the second largest market for
acute intermittent porphyria globally. The favorable factors supporting the
market expansion in the region are initiatives undertaken by the governments
and the availability of funds for
research & development activities. The presence of developed economies in
the region is also likely to propel the
market growth.
Asia Pacific will exhibit the
steepest rise in growth of the market. The increasing geriatric population in
the region is one of the primary drivers of the market. Asian Development Bank
has estimated that by 2050, 15% of the total population of Malaysia will be
from over 65 years age group, and in China, the aging population will surpass
300 million. Furthermore, the booming healthcare sector, technological
developments, huge patient population,
high healthcare expenditure, etc. will
favor the market proliferation throughout the projection period.
The Middle East & Africa will exhibit
sluggish growth due to limited screening, ignorance of diseases, and poor access to treatment.
Competitive
Dashboard:
The Acute
Intermittent Porphyria Market players profiled by MRFR in its report include
Dahaner (U.S.), Bio-Rad Laboratories, Inc.
(U.S.), Siemens AG (U.S.), Sysmex Corporation (Japan), ARKRAY, Inc.
(Japan), ACON Laboratories, Inc. (U.S.), and, F. Hoffmann-La Roche Ltd
(Switzerland) among others. The players strive
to gain prominence in the market by devising and employing strategies
such as research & development, clinical trials, acquisitions &
mergers, innovative collaborations, agreements, etc.
Industry
Developments:
In January 2018, Alnylam Pharmaceuticals,
Inc., a biopharmaceutical company, has announced the expansion of Alnylam Act.
The program will include free third-party genetic testing and counseling for
Acute Hepatic Porphyrias (AHPs) which include four diseases- acute intermittent
porphyria, hereditary deficit of
delta-aminolevulinic acid dehydratase, hereditary coproporphyria, and, variegate porphyria.
For More Information, Please Visit @ Market Research Future
0 Comments